Fallopian tube neoplasm
diseaseOn this page
Also known as fallopian tube neoplasm (disease)fallopian tube tumorfallopian tube tumourneoplasm of fallopian tubeneoplasm of the fallopian tubetumor of fallopian tubetumor of the fallopian tubetumour of fallopian tubetumour of the fallopian tube
Summary
Fallopian tube neoplasm (MONDO:0021092) is a cancer (an umbrella term covering 5 Mondo subtypes) and 52 clinical trials. Top therapeutic interventions include bevacizumab, doxorubicin, and gemcitabine. A subtype of fallopian tube disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 52
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | fallopian tube neoplasm |
| Mondo ID | MONDO:0021092 |
| MeSH | D005185 |
| NCIT | C3032 |
| SNOMED CT | 126916003 |
| UMLS | C0015558 |
| MedGen | 8775 |
| Anatomy (UBERON) | UBERON:0003889 |
| Is cancer (heuristic) | yes |
Also known as: fallopian tube neoplasm · fallopian tube neoplasm (disease) · fallopian tube tumor · fallopian tube tumour · neoplasm of fallopian tube · neoplasm of the fallopian tube · tumor of fallopian tube · tumor of the fallopian tube · tumour of fallopian tube · tumour of the fallopian tube
Disease family
This is a subtype of fallopian tube disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › fallopian tube disorder › fallopian tube neoplasm
Related subtypes (5): fallopian tube endometriosis, salpingitis, embryonic cyst of fallopian tube, tubal pregnancy, hydrosalpinx
Subtypes (5): fallopian tube benign neoplasm, fallopian tube cancer, fallopian tube mucinous tumor, fallopian tube germ cell tumor, fallopian tube endometrioid tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 14 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Bevacizumab | Approved (phase 4) |
| Mirvetuximab Soravtansine | Approved (phase 4) |
| Alvimopan | Phase 3 (in late-stage trials) |
| Atezolizumab | Phase 3 (in late-stage trials) |
| Binimetinib | Phase 3 (in late-stage trials) |
| Carboplatin | Phase 3 (in late-stage trials) |
| Cisplatin | Phase 3 (in late-stage trials) |
| Doxorubicin | Phase 3 (in late-stage trials) |
| Gemcitabine | Phase 3 (in late-stage trials) |
| Ifosfamide | Phase 3 (in late-stage trials) |
| Isophenoxodiol | Phase 3 (in late-stage trials) |
| Paclitaxel | Phase 3 (in late-stage trials) |
| Patupilone | Phase 3 (in late-stage trials) |
| Rucaparib | Phase 3 (in late-stage trials) |
| Thalidomide | Phase 3 (in late-stage trials) |
| Trebananib | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aldesleukin, Alisertib, Allopurinol, Amifostine, Belinostat, Bicalutamide, Capecitabine, Carboxyamidotriazole, Cyclosporine, Decitabine, Denileukin Diftitox, Epoetin Beta, Erlotinib, Farletuzumab, Filgrastim, Fludarabine, Fludarabine Phosphate, Ganciclovir, Gefitinib, INTERFERON GAMMA-1B, Irinotecan, Irofulven, Letrozole, Methylprednisolone, Mifepristone, Nintedanib, Nogapendekin Alfa, Olaparib, Oregovomab, Oxaliplatin, Panitumumab, Pazopanib, Pegfilgrastim, Pembrolizumab, Pemetrexed, Pertuzumab, Regorafenib, Ribociclib, Saracatinib, Sargramostim, Sunitinib, Tasisulam, Temsirolimus, Tetanus Toxoid, Tisotumab Vedotin, Tivozanib, Topotecan, Trabectedin, Tremelimumab, Vandetanib, Veliparib, Vinorelbine.
Clinical trials & evidence
Clinical trials
Clinical trials: 52.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 17 |
| Not specified | 14 |
| PHASE3 | 9 |
| PHASE1 | 9 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01932125 | PHASE4 | COMPLETED | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
| NCT04111978 | PHASE3 | RECRUITING | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) |
| NCT04498117 | PHASE3 | ACTIVE_NOT_RECRUITING | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery |
| NCT05116189 | PHASE3 | ACTIVE_NOT_RECRUITING | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). |
| NCT05257408 | PHASE3 | ACTIVE_NOT_RECRUITING | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
| NCT07213804 | PHASE3 | RECRUITING | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer |
| NCT00191607 | PHASE3 | COMPLETED | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. |
| NCT00191646 | PHASE3 | COMPLETED | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
| NCT00443196 | PHASE2/PHASE3 | COMPLETED | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas |
| NCT01462890 | PHASE3 | COMPLETED | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer |
| NCT01846611 | PHASE3 | COMPLETED | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT04807166 | PHASE2 | ACTIVE_NOT_RECRUITING | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer |
| NCT05605535 | PHASE2 | ACTIVE_NOT_RECRUITING | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer |
| NCT06638931 | PHASE2 | RECRUITING | Agnostic Therapy in Rare Solid Tumors |
| NCT00035100 | PHASE2 | COMPLETED | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
| NCT00063401 | PHASE2 | COMPLETED | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
| NCT00074867 | PHASE2 | COMPLETED | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer |
| NCT00103545 | PHASE1/PHASE2 | COMPLETED | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response |
| NCT00112086 | PHASE2 | COMPLETED | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 |
| NCT00189345 | PHASE2 | COMPLETED | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients |
| NCT00391118 | PHASE2 | COMPLETED | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (Sugar Pill) |
| NCT00445549 | PHASE2 | TERMINATED | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00698451 | PHASE2 | COMPLETED | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
| NCT01131039 | PHASE2 | WITHDRAWN | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| NCT01313078 | PHASE2 | COMPLETED | Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
| NCT01681368 | PHASE2 | TERMINATED | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer |
| NCT01766622 | PHASE2 | WITHDRAWN | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant |
| NCT03648489 | PHASE2 | COMPLETED | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) |
| NCT04556071 | PHASE2 | UNKNOWN | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer |
| NCT04196257 | PHASE1 | RECRUITING | BP1001-A in Patients With Advanced or Recurrent Solid Tumors |
| NCT05617755 | PHASE1 | ACTIVE_NOT_RECRUITING | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer |
| NCT00006155 | PHASE1 | COMPLETED | SU5416 and Carboplatin to Treat Ovarian Cancer |
| NCT00407407 | PHASE1 | TERMINATED | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma |
| NCT01279291 | PHASE1 | TERMINATED | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer |
| NCT01478685 | PHASE1 | COMPLETED | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors |
| NCT02658214 | PHASE1 | COMPLETED | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
| NCT02903771 | PHASE1 | COMPLETED | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. |
| NCT05194072 | PHASE1 | TERMINATED | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors |
| NCT03976999 | Not specified | RECRUITING | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers |
| NCT04794322 | Not specified | RECRUITING | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 6 |
| DOXORUBICIN | 4 | 2 |
| GEMCITABINE | 4 | 2 |
| AMINOCAPROIC ACID | 4 | 1 |
| ASPARAGINASE | 4 | 1 |
| NIRAPARIB | 4 | 1 |
| TOPOTECAN | 4 | 1 |
| TRABECTEDIN | 4 | 1 |
| VANDETANIB | 4 | 1 |
| OREGOVOMAB | 3 | 2 |
| ENZASTAURIN | 3 | 1 |
| PATUPILONE | 3 | 1 |
| SEMAXANIB | 3 | 1 |
| BIRINAPANT | 2 | 1 |
| FELMETATUG VEDOTIN | 2 | 1 |
| OSI-632 | 2 | 1 |
| KHK-2866 | 1 | 1 |
| CHEMBL5175478 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |